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ABSTRACT
Recent data has demonstrated that the pathophysiology of severe COVID-19 infection is associated
with a significant pulmonary coagulopathy. Thrombotic complications have been reported in
approximately 35-45% of patients with severe COVID-19. Entry of SARS-CoV-2 into the host cells
leads to dysregulation in inflammatory signalling pathways, disrupting the normal coagulation
mechanism. The hypercoagulability with abnormal clot formation is attributed to the inappropriately
elevated immune response, culminating in a ‘cytokine storm’ with high levels of pro-inflammatory
cytokines and subsequent thrombosis. The coagulopathy in COVID-19 affects many coagulation
parameters such as D-dimer levels, fibrinogen levels, platelet count and prothrombin time. Coagulation
parameters must be carefully monitored as they may indicate the requirement for clinical intervention.
This suggests prophylactic anticoagulant treatment may be considered for COVID-19 patients with a
predisposition to thrombosis. Current research indicates that immunomodulatory therapy may be
beneficial to limit the propagation of the immune response. However, retrospective well-controlled
studies are required to ensure that adverse effects do not outweigh therapeutic benefits. Despite the
worldwide collaborative effort to elucidate COVID-19 pathophysiology, it is clear that further research
and data analysis is required to uncover the immune mechanism causing the ‘cytokine storm’ in
COVID-19 patients as well as therapeutic regimes to enable correct patient management and treatment
of COVID-19 associated coagulopathies.

INTRODUCTION
As of February 2021, the World Health Organisation (WHO) has reported over 100 million COVID-19
cases globally, with over 2 million deaths. While the majority of COVID-19 cases are mild or
asymptomatic, a small proportion of patients develop complications such as pneumonia, sepsis,
respiratory failure and thromboembolisms (Miesbach and Makris, 2020). Recent data has shown that
the pathophysiology of severe COVID-19 infection has an association with a significant pulmonary
coagulopathy, with thrombotic complications reported in up to 35-45% of patients with severe COVID19 (Levi et al., 2020).
Preliminary studies reported the occurrence of venous thromboembolism (VTE) in 25% of severe
COVID-19 cases admitted to ICU, with a mortality rate of 40%. Despite prophylactic anticoagulation,
a later study reported a 31% incidence of VTE in critically ill COVID-19 cases. Additionally, autopsy
reports have linked pulmonary embolism (PE) to 33% of COVID-19 deaths (Görlinger et al., 2020).
Post-mortem analyses of COVID-19 patients show the formation of microthrombi in the lungs (Martín‐
Rojas et al., 2020). Reports have shown that COVID-19 patients may present with a thromboembolic
event in even asymptomatic cases (Zheng et al., 2020).
The coagulopathy associated with COVID-19 is comparable to that of severe acute respiratory
syndrome (SARS). The pathophysiology involves damage to alveolar tissue by the virus, which can be
exacerbated by mechanical ventilation, leading to the consumption of platelets due to platelet activation
and aggregation (Jiang et al., 2020). Entry of SARS-CoV-2 into the host cells leads to dysregulation in
inflammatory signalling pathways, disrupting the normal coagulation mechanism. The
hypercoagulability with abnormal clot formation is attributed to the inappropriately elevated immune
response, culminating in a ‘cytokine storm’ with high levels of pro-inflammatory cytokines and
subsequent aberrant thrombotic events (Jose and Manuel, 2020).
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The coagulopathy in COVID-19 affects many coagulation parameters such as D-dimer levels,
fibrinogen levels, platelet count and prothrombin time. Critically ill COVID patients have an elevated
D-dimer level which correlates to disease severity; underpinning the potential prognostic value of Ddimer levels in COVID-19 patients (Yao et al., 2020). Coagulation parameters must be carefully
monitored as they may indicate the requirement for clinical intervention. This suggests prophylactic
anticoagulant therapy should be considered for COVID-19 patients with a predisposition to thrombosis
(Buijsers et al., 2020).
Despite the worldwide collaborative effort to elucidate COVID-19 pathophysiology, it is clear that
further research and data analysis is required to uncover the immune mechanism causing the ‘cytokine
storm’ in COVID-19 patients, as well as therapeutic regimes to enable correct patient management and
treatment of COVID-19 associated coagulopathies. The aim of this review was to provide a
comprehensive overview of the pathophysiology of the COVID-19 associated coagulopathy, affected
laboratory parameters and potential therapeutic regimes.

PATHOPHYSIOLOGY OF SARS-CO-V-2 COAGULOPATHY
The pathophysiology of COVID-19 associated coagulopathy can be attributed to the hypercoagulable
state manifested due to an imbalance between proinflammatory signalling cascades and its effect on
coagulation when infected by COVID-19. It has been hypothesised that thrombosis is an immune
mechanism to restrict dissemination of SARS-CoV-2 in vivo and lower the viral load (Colling and
Kanthi, 2020).

THE ROLE OF ACE2 RECEPTORS IN COVID-19 INFECTION
The causative agent of COVID-19 is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
SARS-CoV-2 enters the host cells via binding the angiotensin-converting enzyme 2 (ACE2) receptor.
This receptor is highly expressed on ciliated airway epithelial cells and type-2 alveolar pneumocytes in
the lungs. It has been reported that SARS-CoV-2 spreads systemically throughout the body via infected
pulmonary epithelium and then via pulmonary endothelium. The cellular damage triggers a
proinflammatory coagulation cascade as well as increasing microvascular permeability (Yi et al., 2020).
During SARS-CoV-19 infection, membrane-bound ACE2 (mACE2) is cleaved by the metalloprotease
ADAM-17 leading to the shedding and release of soluble ACE2. This process is associated with
pulmonary injury (Swärd et al., 2020). The decreased ACE2 activity leads to an increase in vascular
permeability triggering the release of tissue factor in endothelial cells, further enriching the
hypercoagulable milieu. ACE2 is thought to have antithrombotic properties, especially in control of the
renin-angiotensin system (RAS) where ACE converts angiotensin I to angiotensin II which is then
degraded by ACE2 (Ni et al., 2020). However, COVID-19 patients have increased levels of angiotensin
II, which leads to the activation of plasminogen activator inhibitor 1 (PAI-1), inhibiting fibrinolysis.
The increase in plasma angiotensin II correlates to increased viral load and subsequent pulmonary injury
(Gue and Gorog, 2020). As seen in figure 1, the downregulation of ACE2 in COVID-19 infection
promotes vasoconstriction, hypertrophy and enhances proinflammatory mechanisms (Ni et al., 2020).
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Figure 1: The Renin-Angiotensin system (RAS), ACE2 and the MAS receptor (adapted from Ni et al., 2020
and created using Biorender.com).

Renin converts angiotensinogen to angiotensin I (1-10), while angiotensin I is converted to angiotensin
II by ACE. Angiotensin II then binds to the angiotensin type 1 receptor which promotes inflammation
and vasoconstriction. ACE2 converts angiotensin II to angiotensin (1-7). Angiotensin (1-7) binds to the
MAS receptor which is anti-inflammatory and promotes vasodilation (Ni et al., 2020).
Patient demographics may have a role in the risk of thrombotic complications in COVID-19 patients,
with the Chinese population having up to a 4-fold increased risk when compared to the Caucasian
populations. The risk is most elevated in the African American population. Polymorphisms in particular
genes, such as the plasminogen activator inhibitor-1 (PAI-1) gene, the nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB) promoter and some proinflammatory cytokine genes, increase
the risk of thrombotic complications (Görlinger et al., 2020).
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Figure 2: The role of ACE2 in thrombus formation in COVID-19 (adapted from Gue and Gorag., 2020 and
created using BioRender.com).

Binding of SARS-CoV-2 to ACE2 receptors leads to increased ACE2 shedding, reducing ACE2 activity
leading to increased tissue factor exposure and activation of the extrinsic coagulation pathway.
Additionally, the decreased ACE2 activity leads to increased plasma angiotensin II levels with a
subsequent increase in PAI-1 levels and decreased fibrinolysis (Gue and Gorag., 2020).

VIRCHOW’S TRIAD AND COVID-19 ASSOCIATED COAGULOPATHY
Many studies have implicated COVID-19 as a risk factor for arterial and venous thrombosis. Applying
the basis of Virchow’s triad, malformations in vascular endothelium, stasis in blood flow and blood
hypercoagulability have been reported in COVID-19 patients, predisposing them to the development of
thrombosis. Aberrant endothelial function, the release of PAI-1 and increased activation of platelets are
implicated in this phenomenon. Due to these findings, research should focus on these novel targets to
reduce mortality in COVID-19 (Ahmed et al., 2020).
Recurrent thrombosis occurs in COVID-19 patients despite prophylactic anticoagulation therapy,
especially in ICU admitted COVID-19 patients (Zheng et al., 2020). All 3 elements of Virchow’s triad
are present in varying degrees in conditions such as atrial fibrillation, myocardial infarction and stroke,
indicating these populations may benefit from prophylactic anticoagulation therapy on admission when
diagnosed with COVID-19 to avoid thrombosis development (Ahmed et al., 2020).
As SARS-CoV-19 disseminates through the endothelium, the endothelial damage leads to the release
of tissue factor, instigating the coagulation cascade (Yi et al., 2020). As seen in figure 2, binding of
SARS-CoV-2 to the ACE2 receptor reduces ACE2 activity leading to increased tissue factor exposure
as well as activation of the extrinsic clotting pathway leading to increased risk of thrombosis.
Vasoconstriction and reduced blood flow occur as a result of COVID-19 induced hypoxia, stimulating
the procoagulant properties of the endothelium. This further damages the endothelium and leads to the
release of large von Willebrand factor (vWF) multimers (Joly et al., 2020). Abnormal blood flow is
exacerbated by microthrombi development. Blood stasis is attributed to immobility in hospitalised
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patients. The hypercoagulable state in COVID-19 stems from activation of the coagulation cascade,
aberrant platelet function, complement activation and plasminogen inhibition (Ahmed et al., 2020).

Figure 3: Pathophysiology of thrombosis in COVID-19 (adapted from Joly et al., 2020 and created using
BioRender.com).

Binding of SARS-CoV-19 to the ACE2 receptor leads to an inappropriate release of proinflammatory
cytokines culminating in a cytokine storm which triggers endothelitis and hypercoagulability,
increasing the risk for thrombosis development. As seen in the Figure 3 above, the cytokine storm is
thought to be the instigator of the hypercoagulable state and endothelial damage (Joly et al., 2020).

COVID-19 AND CYTOKINE STORM
The pathophysiology of COVID-19 is currently incompletely understood. However, the viral infection
has been linked to an inappropriately amplified immune response leading to a ‘cytokine storm’ which
has been implicated in abnormal coagulation and subsequently, acute respiratory distress syndrome
(ARDS) and multiorgan failure (MOF). As a result, much interest has been generated in the
identification of cytokines which may represent novel anti-inflammatory therapeutic targets
(Iannaccone et al., 2020). Recent research demonstrates that the coagulopathy produced in COVID-19
is not due to specific properties of the virus, but due to the hyperactive immune response against the
virus. However, unlike other RNA haemorrhagic fever viruses, significant bleeding does not
accompany the coagulopathy in COVID-19 patients (Connors and Levy, 2020).
As seen in figure 3 above, binding of SARS-CoV-2 to respiratory epithelial cells via the ACE2 receptor
elicits an aberrant inflammatory response of a cytokine storm with an influx of proinflammatory
cytokines such as IL-1β, IL-2, IL-6 and TNF. Endothelial damage contributes to hypercoagulability by
stimulating the production of tissue factor, P-selectin, Factor VIII, fibrinogen and vWF. Natural
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anticoagulants such as thrombomodulin (TM) and endothelial protein C receptor (EPCR) are
downregulated (Chan and Weitz, 2020).

Figure 4: Coagulopathy and thrombosis associated with COVID-19 infection (adapted from Chan and
Weitz, 2020 and created using BioRender.com).

As seen in Figure 4 the cytokine storm is fundamental to the progression to the hyperinflammatory state
which leads to the dysregulation of coagulation with associated thrombosis. The coagulopathy can
progress to complications such as ARDS and multiorgan failure and death (Chan and Weitz, 2020).
A hyperactive, overexaggerated immune response against the SARS-CoV-2 virus has been linked to
the high mortality rates in COVID-19 patients. As demonstrated in figure 4 above, the inappropriately
elevated levels of proinflammatory cytokines contributes to the development of ARDS and widespread
tissue damage causing MOF. Reports of COVID-19 patient cytokine panels have demonstrated that the
cytokine storm has a direct association with pulmonary damage and poor prognosis. Proinflammatory
cytokines in this panel include interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-18 (IL-18),
interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α) (Ragab et al., 2020).
However, a preliminary study reported that COVID-19 is not characterised by a cytokine storm, with
much lower levels of proinflammatory cytokines reported in COVID-19 patients vs other critically ill
patients (e.g., bacterial septic shock). Studies have reported that IL-6 levels in severe COVID-19 cases
are increased but are considerably lower than IL-6 level in non-COVID-19 related ARDS. For example,
sepsis patients with ARDS have an IL-6 concentration of 376 pg/ml compared to only 48 pg/ml in
COVID-19 patients with ARDS (Kox et al., 2020). Due to these findings, it is yet to be verified that
cytokine directed therapies can be used to successfully treat the cytokine storm associated with poor
outcome in COVID-19 patients.
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ABNORMAL LABORATORY PARAMATERS IN COVID 19 INFECTION
Abnormal FBC results in COVID-19 and associated coagulopathy
A common finding in the full blood count of COVID-19 patients is lymphopenia with a mild
thrombocytopenia. 5% of COVID-19 patients present with a platelet count less than 100 × 109 cells/L,
while up to 95% of patients with severe disease have a platelet count of less than 150 × 109 cells/L (Levi
et al., 2020). COVID-19 induced thrombocytopenia occurs due to consumption of platelets in response
to endothelial damage, as well as pulmonary microthrombi formation. Platelets in COVID-19 patients
are reported to have an elevated mean platelet volume (MPV). The production of large, immature
platelets may contribute to thrombosis due to their increased reactivity (Wool and Miller, 2020).
Neutrophilia has been reported in some COVID-19 patients (Pourbagheri-Sigaroodi et al., 2020).
Increased neutrophil infiltration in the lungs and formation of neutrophil extracellular traps (NETs)
exacerbate microthrombi formation by enhancing platelet aggregation (Tomar et al., 2020). The absence
of eosinophils at presentation has been reported in 60% of COVID-19 patients compared to 16% of
patients with influenza. This may be useful as a preliminary screen to isolate suspect COVID patients
to prevent further spread of the virus while awaiting confirmatory testing (Tanni et al., 2020). Severe
COVID-19 cases have recently been characterised by a higher neutrophil to lymphocyte ratio (NLR).
An elevated NLR is a risk factor for mortality in infectious diseases (Ragab et al., 2020).
Abnormal coagulation parameters in COVID-19
Some of the abnormal coagulation parameters include a prolonged prothrombin time (PT) and activated
partial thromboplastin time (aPTT). However, in a small subset of patients the aPTT has been shown to
be shortened significantly, probably due to increases in the acute phase reactant FVIII (Wool and Miller,
2020). This phenomenon is encountered with patients on extracorporeal membrane oxygenation
(ECMO). Although bleeding risk with COVID-19 patients is relatively low, it is important to consider
such anomalies before proceeding with anticoagulant therapy (Mazzeffi et al., 2020).
COVID-19 coagulopathy is associated with an abnormal hypercoagulable state which progresses to a
disseminated intravascular coagulopathy (DIC)-like state in the late stages of disease. There are marked
differences between COVID-19 coagulopathy and DIC. In COVID-19 associated coagulopathy, there
is mainly localisation of pulmonary microthrombi while in DIC this is more widespread. Bleeding is
uncommon in COVID-19 coagulopathy while it is common in DIC. Fibrinogen levels are increased in
COVID-19 coagulopathy but decreased in DIC. D-dimer levels are more markedly elevated in COVID19 coagulopathy with a mild thrombocytopenia and mild clotting time prolongation when compared to
DIC (Aggarwal et al., 2020).
COVID-19 associated coagulopathy can be divided into 3 stages. Stage 1 demonstrates an increase in
D-dimer level, stage 2 demonstrates an elevated D-dimer level, mildly prolonged PT +/or aPTT with
mild thrombocytopenia and finally, stage 3 shows a progression towards DIC-typical laboratory
parameters. However, hypofibrinogenemia is rare (Wool and Miller, 2020). Tang et al noted that 71%
of COVID-19 non-survivors developed DIC by day 4 of hospital admission compared to <1% of
survivors, highlighting the importance of monitoring fibrinogen levels, PT and platelet count
(Turshudzhyan, 2020). Due to the marked differences between COVID-19 induced coagulopathy and
DIC, studies have shifted to identify a COVID-19 coagulopathy scoring system as DIC criteria are often
not met (Hadid et al., 2020).
Recent research has demonstrated the presence of antiphospholipid antibodies associated with
coagulopathy in COVID-19 patients which may account for the prolongation of the aPTT (Kipshidze
et al., 2020). The presence of these antibodies may indicate requirements for early anticoagulation
intervention. However, it is not uncommon to find these antibodies in patients with infection (Connell
et al., 2020).
D-dimers have also been implicated as a prognostic marker (Pourbagheri-Sigaroodi et al., 2020).
Research has shown that the increase in D-dimer levels is concurrent with the progressive activation of
the coagulation cascade with simultaneous activation of pulmonary fibrinolysis (Fogarty et al., 2020).
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Inflammatory markers in COVID-19
In severe disease, increased lactate dehydrogenase, serum ferritin and creatine kinase are found.
Progression to multiple organ failure is marked by elevations in creatinine, ALT and AST (Ragab et al.,
2020). The development of severe COVID-19 is denoted by increases in serum amyloid A (Zeng et al.,
2020).
Recent research has identified the importance of lymphopenia as an indicator for development of the
COVID-19 related cytokine storm which precedes the COVID-19 induced coagulopathy. The low
number of T cell lymphocytes fails to control the viral infection and allows inappropriate propagation
of the innate immune system. The ineffective elimination of inflammatory macrophages by CD8+ T
cells may explain the surplus of proinflammatory cytokines (Caricchio et al., 2020). A retrospective
study of 150 COVID-19 patients concluded that elevated ferritin and IL-6 correlates mortality with
hyperinflammation. To identify COVID-19 patients who may benefit from immunosuppression
therapy, increasing ferritin, thrombocytopenia and increased erythrocyte sedimentation rate (ESR)
should be monitored (Mehta et al., 2020). One study correlated increased D-dimer levels with increased
C-reactive protein (CRP), ferritin and procalcitonin (PCT) indicating that inflammatory markers may
have the ability to predict onset of the cytokine storm preceding coagulopathy (Long et al., 2020).
Can biomarkers predict clinical severity and coagulopathy in COVID-19?
As the clinical presentation of COVID-19 ranges from asymptomatic to life-threatening, several studies
have focused on identifying biomarkers to predict the disease course as well as predicting risk of
complications such as thrombosis (Lippi et al., 2020). Biomarkers of coagulation, inflammatory
response as well as clinical scoring systems can predict the clinical progression of COVID-19, patient
outcome and requirement for increasingly scarce hospital resources such as ICU beds and ventilators
(Görlinger et al., 2020).
Platelet counts can be used as an indicative marker of critical COVID-19 cases as thrombocytopenia is
associated with a 3-fold increased risk of severe disease, with an increased mortality rate (Lippi et al.,
2020). The importance of many lab parameters as potential prognostic indicators has been
demonstrated, with findings having the ability to discriminate between mild and severe infection.
Indicators of poor prognosis in COVID-19 patients include a low lymphocyte count and an increased
D-dimer level, lactose dehydrogenase (LDH) and liver enzymes AST and ALT (Levi et al., 2020).
The most promising biomarker for COVID-19 disease severity and progression to aberrant coagulation
is the D-dimer. D-dimer levels are highly elevated in COVID-19 non-survivors compared to survivors.
Studies have shown that D-dimer levels commonly increase as the COVID-19 patient clinically
deteriorates (Zhou et al., 2020). However, the use of D-dimer levels to guide anticoagulation therapy is
not recommended in clinical practice and is reserved for clinical trial settings as further human trials
are required (Flaczyk et al., 2020).

COVID-19 COAGULOPATHY TREATMENT
Therapeutic Anticoagulation
Research has demonstrated that although prophylactic anticoagulation reduces risk of thrombosis, the
risk of major bleeding may increase to unacceptable levels in severely ill COVID-19 patients. Clinical
trials conducting studies on anticoagulation dosing regimes are urgently needed, and fortunately, are in
progress (Chan and Weitz, 2020). A retrospective study of over 4,000 participants demonstrated that
anticoagulation therapy reduced incidence of mortality and intubation in COVID-19 patients (Nadkarni
et al., 2020).
However, there are many clinical considerations before administering anticoagulants to all hospitalised
COVID-19 patients. Some studies recommend administration in the following circumstances: patients
on mechanical ventilation in ICU, non-ICU patients with pre-existing predisposition to thrombosis such
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as diabetics, those with ischemic cardiomyopathy and patients with a history of PE or VTE (Zheng et
al., 2020).
Heparin
Heparin exerts its anticoagulant effect by binding antithrombin III which amplifies its inhibitory effect
on FXa and thrombin. A synthetic analogue, Fondaparinux, is indicated for prophylaxis of VTE
(Costanzo et al., 2020). Heparin has been shown to decrease pulmonary emboli and inflammation of
the lung while potentially acting as an antiviral agent against COVID-19. Other properties of heparin
include the neutralisation of IL-6 and IL-8 that have a role in ARDS (Buijsers et al., 2020).
Low molecular weight heparin (LMWH) in particular plays a very important role in the treatment of
COVID-19 infection through its ability to inhibit heparinase (HPSE). HPSE plays a role in the
disruption of the endothelial glycocalyx barrier which is involved in the pathology of pulmonary
oedema. LMWH inhibits synthesis of TNF-α and IFN-γ by blocking the NF-κB pathway. Heparin has
demonstrated the ability to inhibit complement system activation which is thought to propagate the
coagulopathy and thrombosis found in COVID-19 (Buijsers et al., 2020).
Research has demonstrated that prophylactic heparin administration leads to a 20% decrease in
mortality in patients with an elevated D-dimer level and sepsis-induced coagulopathy score
(Hippensteel et al., 2020). Studies have supported the use of nebulised unfractionated heparin (UFH) to
treat COVID-19 associated ARDS and pneumonia. Also, UFH has a mucolytic effect which may relieve
some of the pneumonic symptoms (Van Haren et al., 2020). Other effects include the release of tissue
factor pathway inhibitor (TFPI), further enhancing its anticoagulative properties (Kipshidze et al.,
2020).
Heparin dose adjustments should be made according to patient’s weight, D-dimer levels, renal function
and development of respiratory failure. UFH is recommended for patients with a reduced creatinine
clearance (<30 ml/min). Increased anticoagulation is required in patients with highly elevated D-dimer
levels. As previously discussed, heparin resistance may be attributed to decreased anti-thrombin levels
and increased levels of fibrinogen. This may indicate the administration of anti-thrombin supplements
which may enhance heparin’s anticoagulative activity (Turshudzhyan, 2020; Zheng et al., 2020).
Although clinicians recommend the transition from vitamin K antagonist anticoagulants to direct oral
anticoagulants (DOACs), further research is required to characterise the pharmacological interactions
between anti-retroviral drugs and DOACs (Turshudzhyan, 2020). Although DOACs exhibit similar
anti-inflammatory properties to heparin, clinical guidance recommends Rivaroxaban and Edoxaban are
not administered with antiviral therapy, while Apixaban should be administered at a half dose.
Dabigatran can be given at the normal dose (Kartsios et al., 2020).
Thrombolytic therapy
Alteplase is a thrombolytic agent that reportedly improves oxygenation in COVID-19 patients. This
treatment could potentially alleviate some of the demand for mechanical ventilation by improving
oxygenation in COVID-19 patients. However major bleeding has been reported in 10% of cases while
intracranial bleeding has been reported in 1-2% of cases following systemic administration of this agent.
As of late, this therapy is not indicated for treatment of COVID-19 related thrombosis (Barnes et al.,
2020). It is recommended that thrombolytic therapy is only administered to those with haemodynamic
instability who are progressively deteriorating (Rosovsky et al., 2020).
Anti-platelet drugs
A recent study has shown that in approximately 20% of COVID-19 patients, SARS-COV-2 RNA is
detected in platelets (Zaid et al, 2020). The platelets also have hyperactive characteristics including
increased degranulation and superior adhesion which contributes to inflammatory thrombus formation.
For this reason, platelet activation pathways may represent a novel target for COVID-19 patients to
prevent complications such as thrombi formation and consumptive coagulopathy (Zaid et al., 2020).
Because thrombosis occurs in COVID-19 patients despite anticoagulation administration, research
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should consider examining the value of antiplatelet drugs. Retrospective studies could be used to
analyse if patients already taking antiplatelet drugs for an underlying disorder (such as cardiomyopathy)
may be safeguarded from severe manifestations of COVID-19 (Thachil, 2020).
Dipyridamole (DIP) is an adenosinergic antiplatelet drug used globally to treat coagulopathy.
Experimental analysis shows that DIP exerts anti-inflammatory and antiviral properties in COVID-19
cases (Liu et al., 2020). A limited clinical trial of COVID-19 patients demonstrated reduced D-dimer
levels when treated with DIP. As DIP is universally available and moderately inexpensive with a high
safety profile, further research is required to make use of this valuable antiplatelet agent (Colling and
Kanthi, 2020).
Immune therapies
Due to the hyperactivation of the immune system, caused by SARS-CoV-2 infection, research has
focused on targeting inflammatory signalling pathways to reduce the immune impact. Such therapies
include disease-modifying anti-rheumatic drugs such as Tociluzimab, Baricitinib, Anakinra and
hydroxychloroquine (Zhong et al., 2020). Once the cytokine storm has been activated, targeting
upstream pathways may be more successful to limit the amplification of the hypercoagulable pathway
(Colling and Kanthi, 2020).
Tocilizumab
IL-6 levels are elevated in COVID-19 patients, with its levels correlating to risk of mortality. Data
suggests that IL-6 plays an important role in lung pathology in COVID-19 patients, indicating that it is
an appropriate target for immunomodulatory therapy. Tocilizumab is a humanised IL-6 receptor
antagonist which is clinically approved for treatment of rheumatoid arthritis and cytokine release
syndrome. As COVID-19 associated pneumonia is thought to be attributed to the COVID-19 cytokine
storm, research has shifted towards immune targeted therapies like Tocilizumab. Administration of
Tocilizumab leads to a stable or decreased level of IL-6 as the drug competitively binds to IL-6 receptors
(Song et al., 2020).
A preliminary trial in China used the monoclonal anti-IL-6 antibody Tocilizumab to target the cytokine
storm associated with COVID-19 leading to a decrease in mortality and fewer mechanical ventilation
requirements. The FDA has approved clinical trials to phase III for therapeutic utilisation of tocilizumab
in 330 patients with severe COVID-19 related pneumonia (Ragab et al., 2020). Tocilizumab is still in
its infancy for treatment of COVID-19 pneumonia. Randomised studies are required to confirm these
findings, determine the optimal dose required, along with the critical timing of administration (Guaraldi
et al., 2020)
Tocilizumab treatment has been associated with neutropenia and thrombocytopenia (McCreary and
Pogue, 2020). Further studies are required to determine if Tociluzimab has a beneficial role in the
prevention of COVID-19 associated thrombosis.
Baricitinib
Baricitinib is a Janus kinase inhibitor with anti-inflammatory properties currently used to treat
rheumatoid arthritis. This therapy can reduce the influx of cytokines associated with the COVID-19
cytokine storm (Cantini et al., 2020). As the severe phase of COVID-19 is characterised by high proinflammatory cytokine levels and all of these implicated cytokines signal through the JAK-STAT
transcription pathway, this immune therapy could potentially downregulate the COVID-19 associated
cytokine storm. As illustrated in figure 5 below, Baricitinib selectively binds to JAK1/JAK2 and acts
as a reversible ATP competitive kinase inhibitor. This suppresses the level of pro-inflammatory
cytokines, primarily IL-6, IL-12 and IFN-γ. The reduction in the level of these cytokines can potentially
reduce the inflammatory damage caused to the lungs and other organs in COVID-19 infection. SARSCoV-2 viral endocytosis is reduced by Baricitinib due to its high affinity for AP2-associated protein
kinase which acts as a regulator of clathrin-mediated viral endocytosis (X. Zhang et al., 2020).
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However, there are reservations regarding JAK inhibitors in treatment of viral infection as the JAKSTAT signalling pathway leads to interferon production which kills virus infected cells (Favalli et al.,
2020). However, the dose dependent association with thromboembolic events requires more research.
As a result, this drug is only FDA approved at the 2 mg/day dose to reduce the risk of thrombotic events.
Platelet count is exponentially increased in the first two weeks of Baricitinib therapy but there is no
evidence to support that this is responsible for the hyperthrombotic state as another JAK inhibitor,
tofacitinib, does not increase platelet count but also has an increased risk of thrombotic events. As a
result, although Baricitinib may decrease the COVID-19 induced cytokine storm, therapeutic benefits
may be outweighed by its adverse hypercoagulable risks (Jorgensen et al., 2020). There is currently an
ongoing trial of Baricitinib therapy administered with the antiviral Remdesivir which may clarify the
benefits of this therapy (Titanji et al., 2020).

Figure 5: Baricitinib acts intracellularly to suppress the activation of JAKs, subsequently prohibiting the
cytokine storm (adapted from X. Zhang et al., 2020 and created using BioRender.com).

When SARS-CoV-2 binds to ACE2, a large amount of cytokines such as IL-6 and IFN-γ are released.
The pro-inflammatory cytokines bind to their receptors and activate JAKs which leads to the
downstream activation and phosphorylation of STATs. The phosphorylated STATs enter the nucleus
and lead to transcription of cytokine-responsive genes, culminating in a cytokine storm (X. Zhang et
al., 2020).
Hydroxychloroquine
Hydroxychloroquine has demonstrated beneficial effects in vitro for control of COVID-19 associated
coagulopathy. Studies have shown the anti-thrombotic properties of hydroxychloroquine in animal
models by inhibition of platelet aggregation and reduced antiphospholipid antibody binding. The exact
mechanism by which hydroxychloroquine exerts its anticoagulative effects is still largely unknown (Pal
et al., 2020). Many studies demonstrated no in vivo clinical benefits of hydroxychloroquine in COVID19 treatment or prevention (Li et al., 2020).
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Intravenous immunoglobulin (IvIg)
Intravenous immunoglobulin (IVIg) is derived from human plasma and is used to treat
autoinflammatory diseases due to its potent immunomodulatory abilities. Although, IVIg was used in
the SARS 2003 epidemic to treat the associated cytopenias, there is no substantial clinical evidence for
its use in the treatment of COVID-19 (Song et al., 2020). Also, there is apprehension that IVIg may
trigger an inappropriate immune response termed antibody-dependent enhancement (ADE) (Nguyen et
al., 2020). As complement is activated in COVID-19, monoclonal antibodies such as Eculizumab could
be effective in dampening COVID-19 pathophysiology (Ahmed et al., 2020). It is clear that additional
research is required to analyse the potential prothrombotic effect of IVIg in COVID-19 (Muccioli et al.,
2020).
General COVID-19 Treatment
COVID-19 treatment is predominantly supportive. However, one must consider the effect of these
therapies on the COVID-19 associated coagulopathy, especially in patients with one or more risk factors
for thrombosis. Based on the results of preliminary studies, the FDA issued emergency authorisation of
the use of the antiviral Remdesivir for treatment of hospitalised COVID-19 patients in the USA in May
(Beigel et al., 2020). However, deep vein thrombosis (DVT) has been reported in COVID-19 recipients
of Remdesivir. Further studies are required to determine if this antiviral agent increases the risk of
coagulopathy in COVID-19 (Fan et al., 2020). Animal models have demonstrated that the
corticosteroid, Dexamethasone, decreases the formation of neutrophil extracellular traps (NETs) which
have been identified in COVID-19 coagulopathy (Fan et al., 2020, Arabi et al., 2020).

CONCLUSION
To conclude, despite worldwide collaboration, there is no clinically supported prophylactic
anticoagulation regime to treat the coagulopathy associated with severe COVID-19 infection. This
review has discussed the possible aetiology of the COVID-19 associated coagulopathy, affected lab
parameters and prognostic indicators, as well as the requirement for anticoagulant therapy and potential
novel therapeutic targets.
Contemporary data demonstrate that the COVID-19 coagulopathy is triggered by a ‘cytokine storm’
and due to this finding, research has queried that targeting this cytokine storm may represent a budding
therapeutic entity to reduce the mortality associated with COVID-19 coagulopathy. However, some
studies have shown that both incidence of coagulopathy and proinflammatory cytokine levels in general
ICU patients and COVID-19 ICU patients are comparable which undermines the studies that suggest
that the cytokine storm, and subsequent coagulopathy leading to a hyperthrombotic state, are unique to
severe COVID-19 cases (Kox et al., 2020). Due to these findings, it is yet to be verified that cytokine
directed therapies can be used to successfully treat the cytokine storm associated with poor outcome in
COVID-19 patients.
The monitoring of FBC parameters is important in management of COVID-19 patients and progression
to COVID-19 coagulopathy. Due to the abnormal coagulation parameters observed in COVID patients,
the importance of multidisciplinary medical science in the management of COVID patients has been
highlighted. Monitoring of coagulation parameters is paramount to reducing COVID-19 related
mortality as certain thresholds may indicate the requirement for clinical intervention before the
development of thrombosis.
Although guidelines have been published on indicative criteria for anticoagulation therapy in COVID19, no guidelines have been adopted universally (Flaczyk et al., 2020). The two main approaches in the
treatment and prevention of COVID-19 coagulopathy include both therapeutic and prophylactic
anticoagulation as well as immunomodulatory therapies which target the inflammatory signalling
cascade. Several plausible candidates have been applied to treatment of COVID-19 in attempt to reduce
the occurrence of the potentially fatal coagulopathy. However, therapeutic benefits may not compensate
for the adverse effects.
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As a final remark, many studies support that COVID-19 associated coagulopathy is triggered by a
cytokine storm. It is clear that retrospective randomised studies and clinical trials are required to validate
anticoagulation regimes for COVID-19 coagulopathy, as well as identification of laboratory cut-off
values to flag patients at risk of thrombosis.
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